Patrick-Mahaffy
- Mapper since:
- April 02, 2024
- Last map edit:
- No activity yet
A seasoned leader in oncology-focused biotechnology, specializing in drug development and commercialization in the US and Europe, Patrick Mahaffy has led multiple firms within the industry from Boulder, Colorado, and is currently based in South Florida.
With a rich background in biotech, he most recently held the CEO position at Clovis Oncology, a company he co-founded in 2009. His leadership saw the development and commercialization of treatments for ovarian and prostate cancer in the US and Europe, along with the initiation of early-stage clinical trials for a novel targeted radionuclide therapy in oncology. Despite its promising start, the company ceased operations in late 2022, affected by COVID-19’s impact on cancer diagnoses and FDA concerns about a class of drugs for ovarian cancer treatment.
Before his role at Clovis, he served as CEO at Pharmion from 2000 to 2008, until its acquisition by Celgene (now part of Bristol Myers Squibb), and at Nexstar Pharmaceuticals from 1992 to 1998, before Gilead Sciences acquired it. Both companies thrived under his leadership, launching new oncology drugs in the US and Europe.
The drugs developed and marketed during his tenure at these three companies continue to be either the standard of care or part of the standard treatment for their respective conditions.
His professional journey began at Warburg Pincus as an investment banker from 1986 to 1992.
He holds a Master’s degree in International Affairs from Columbia University, completed in 1986, following his Bachelor’s degree in the same field from Lewis and Clark College, obtained a year earlier.
Portfolio: https://patrickmahaffy.com